Drug Study Archives - BCDiabetes

Petition: Lobby BC Pharmacare to cover lifesaving SGLT2 inhibitor diabetes treatment

Living With Diabetes

BCDiabetes Medical Director, Dr. Tom Elliott, has launched a petition to lobby BC Pharmacare to cover SGLT2 inhibitors. As many as 50,000 British Columbians would likely benefit from SGLT2 inhibitors, but many do not have funds or coverage. This class of drug has been shown to reduce mortality for those at high risk of heart […]

READ MORE

New Study Questions Effectiveness of Type 2 Diabetes Treatment

Living With Diabetes,Research

New study questions Type 2 diabetes treatment “No evidence glucose-lowering drugs help ward off long-term complications, researchers say.” This is a massive statement so we sought our medical director, Dr. Tom Elliott, for insight.   The CBC recently reported on a publication by Dr. Victor Montori, of the Mayo Clinic in Circulation: Cardiovascular Quality and Outcomes arguing a […]

READ MORE

Important Type 2 Diabetes Results Reported

Living With Diabetes,Research

Today the results of 2 important studies in Type 2 diabetes presented at the annual American Diabetes Association meeting in New Orleans this week were published in the prestigious New England Journal of Medicine. The LEADER study examined the outcomes of 9,340 patients with Type 2 diabetes followed for four years. All took standard diabetes […]

READ MORE

New Study To Test Whether GLP-1 Agents Help You or Hurt You Before Taking The Drug

Announcements,Research

We are very excited about this made-in-BC research to help us find out if a drug will be beneficial for those taking it or whether it might make them ill before ever taking the drug. From Dr. Tom Elliott: “A new class of medication for diabetes known as GLP-1 agents have been on the Canadian market […]

READ MORE

BC Diabetes Joins PERL Study

Announcements,Research

We are very happy to announce that we have been added to a prestigious roster or institutions and organizations from across North America. This study is examining how a drug might help prevent kidney disease in people with Type 1 diabetes. To hear from the principal investigators, please click here to watch a brief video […]

READ MORE

U.S. FDA warns on SGLT2 inhibitors, a class of type 2 diabetes drugs

Announcements,Research

This past Friday the US Federal Drug Administration released a warning that some newer type 2 diabetes drugs, known as SGLT2 inhibitors, may cause ketoacidosis, or dangerously high levels of blood acids that could require hospitalization. The warning comes from the US, but what does this mean for Canada. Our Medical Director, Dr. Tom Elliott, lets us know. […]

READ MORE

Our new Type 1 diabetes study puts us in the spotlight

Announcements,News & Media,Research

  We have had a very busy week as news of our latest Type 1 diabetes study, sponsored by UBC and the JDRF Canadian Clinical Trials Network, is making the news. In the past 48 hours, our medical director, Dr. Tom Elliott, along with various members of our team and study participants, have appeared on the […]

READ MORE
Translate »